SI1841432T1 - Sestavki za obrambo proti odpornosti na antibiotike, ki jo povzroäśa beta-laktamaza z uporabo inhibitorja beta-laktamaze primernega za injektiranje - Google Patents

Sestavki za obrambo proti odpornosti na antibiotike, ki jo povzroäśa beta-laktamaza z uporabo inhibitorja beta-laktamaze primernega za injektiranje

Info

Publication number: SI1841432T1
Authority: SI; Slovenia
Prior art keywords: beta; lactamase; compositions; normally; sodium
Prior art date: 2004-12-02

Application number

SI200531130T

Other languages

English (en)

Inventor

Manu Chaudhary

Original Assignee

Venus Remedies Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-02

Filing date

2005-11-28

Publication date

2011-02-28

2005-11-28 Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd

2011-02-28 Publication of SI1841432T1 publication Critical patent/SI1841432T1/sl

Links

239000000203 mixture Substances 0.000 title abstract 4
108090000204 Dipeptidase 1 Proteins 0.000 title abstract 2
239000003781 beta lactamase inhibitor Substances 0.000 title abstract 2
102000006635 beta-lactamase Human genes 0.000 title abstract 2
229940126813 beta-lactamase inhibitor Drugs 0.000 title abstract 2
230000003115 biocidal effect Effects 0.000 title abstract 2
238000002347 injection Methods 0.000 title abstract 2
239000007924 injection Substances 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 2
NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 abstract 2
229960000479 ceftriaxone sodium Drugs 0.000 abstract 2
FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
229960000614 sulbactam sodium Drugs 0.000 abstract 2
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
229960004755 ceftriaxone Drugs 0.000 abstract 1
VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 abstract 1
239000002738 chelating agent Substances 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
238000007918 intramuscular administration Methods 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
229960005256 sulbactam Drugs 0.000 abstract 1
FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 abstract 1
229940126085 β‑Lactamase Inhibitor Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

SI200531130T 2004-12-02 2005-11-28 Sestavki za obrambo proti odpornosti na antibiotike, ki jo povzroäśa beta-laktamaza z uporabo inhibitorja beta-laktamaze primernega za injektiranje SI1841432T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN2411DE2004		2004-12-02
PCT/IN2005/000382 WO2006059344A1 (en)	2004-12-02	2005-11-28	Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection
EP05817957A EP1841432B1 (en)	2004-12-02	2005-11-28	Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection

Publications (1)

Publication Number	Publication Date
SI1841432T1 true SI1841432T1 (sl)	2011-02-28

Family

ID=35789266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200531130T SI1841432T1 (sl)	2004-12-02	2005-11-28	Sestavki za obrambo proti odpornosti na antibiotike, ki jo povzroäśa beta-laktamaza z uporabo inhibitorja beta-laktamaze primernega za injektiranje

Country Status (23)

Country	Link
US (2)	US8273732B2 (sl)
EP (1)	EP1841432B1 (sl)
JP (1)	JP5269415B2 (sl)
KR (2)	KR101244362B1 (sl)
CN (1)	CN101060846A (sl)
AT (1)	ATE476981T1 (sl)
AU (1)	AU2005310888B2 (sl)
BR (1)	BRPI0517128A (sl)
CY (1)	CY1110886T1 (sl)
DE (1)	DE602005022939D1 (sl)
DK (1)	DK1841432T3 (sl)
ES (1)	ES2349301T3 (sl)
HR (1)	HRP20100591T1 (sl)
MX (1)	MX2007006540A (sl)
NZ (1)	NZ555075A (sl)
PL (1)	PL1841432T3 (sl)
PT (1)	PT1841432E (sl)
RS (1)	RS51506B (sl)
RU (1)	RU2397768C2 (sl)
SI (1)	SI1841432T1 (sl)
UA (1)	UA91204C2 (sl)
WO (1)	WO2006059344A1 (sl)
ZA (1)	ZA200704394B (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030010176A (ko) *	2001-07-25	2003-02-05	이병두	은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129381B (zh) *	2006-08-25	2012-02-01	天津和美生物技术有限公司	含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) *	2006-08-25	2013-12-25	天津和美生物技术有限公司	含β-内酰胺类抗生素和缓冲组分的抗生素复方
JP5639471B2 (ja) *	2008-07-28	2014-12-10	惠三山口	感染症治療効果増強剤
CN101537009B (zh) *	2009-04-30	2010-09-15	海口奇力制药股份有限公司	注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) *	2009-05-19	2012-09-13	Mitsubishi Tanabe Pharma Corp	２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
RU2593363C2 (ru) *	2011-05-28	2016-08-10	Вокхардт Лимитед	Композиции, включающие антибактериальное средство и тазобактам
EP2768503A1 (en) *	2011-07-26	2014-08-27	Wockhardt Limited	Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) *	2011-09-23	2013-03-28	Manu Chaudhary	Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
SG11201405799TA (en)	2012-03-26	2014-11-27	Santen Pharmaceutical Co Ltd	Ophthalmic solution comprising diquafosol
RU2650962C2 (ru)	2012-06-07	2018-04-18	Чилдрен'З Хоспитал Лос Анджелес	Способы лечения нейтропении с применением ретиноидных агонистов
AU2013323280A1 (en) *	2012-09-27	2015-04-09	Merck Sharp & Dohme Corp.	Tazobactam arginine antibiotic compositions
AU2015219038B2 (en)	2014-02-18	2018-10-18	Children's Hospital Los Angeles	Compositions and methods for treating neutropenia
IN2014MU01194A (sl) *	2014-03-29	2015-10-02	Wockhardt Ltd
SG11201509950TA (en) *	2014-04-03	2016-01-28	Kewpie Kabushiki Kaisha Also Trading As Kewpie Corp	Injection fluid bag and injection preparation
US10201518B2 (en)	2016-09-28	2019-02-12	The University Of Hong Kong	Bismuth(III) compounds and methods thereof
EP3429592A4 (en) *	2016-11-02	2019-10-30	Xiangbei Welman Pharmaceutical Co., Ltd	COMPOSITION OF CEFTRIAXONNATRIUM AND SULBACTUMNATRIUM
CN111249284B (zh) *	2016-11-03	2022-10-04	湘北威尔曼制药股份有限公司	治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠
RU2665006C1 (ru) *	2017-02-28	2018-08-24	Общество с ограниченной ответственностью "Супербаг Солюшенс"	Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
EP3833665B1 (en)	2018-08-09	2023-07-19	Antabio SAS	Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en)	2018-08-09	2024-02-20	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
MX2023007135A (es)	2020-12-17	2023-08-25	Idexx Lab Inc	Detección y tratamiento de la fiebre de las montañas rocosas.
WO2025165991A1 (en) *	2024-01-31	2025-08-07	The Penn State Research Foundation	Biopolymeric anti-antibiotics and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6630510B1 (en) *	1999-10-28	2003-10-07	Merck & Co., Inc.	Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) *	2000-01-20	2004-01-13	Hoffmann-La Roches Inc.	Parenteral bisphosphonate composition with improved local tolerance
PT1468697E (pt) *	2003-04-14	2008-03-05	Wyeth Corp	Composições contendo piperacilina e tazobactam úteis para injecção

2005
- 2005-11-28 HR HR20100591T patent/HRP20100591T1/hr unknown
- 2005-11-28 PT PT05817957T patent/PT1841432E/pt unknown
- 2005-11-28 DK DK05817957.3T patent/DK1841432T3/da active
- 2005-11-28 WO PCT/IN2005/000382 patent/WO2006059344A1/en not_active Ceased
- 2005-11-28 US US11/720,710 patent/US8273732B2/en not_active Expired - Fee Related
- 2005-11-28 AU AU2005310888A patent/AU2005310888B2/en not_active Ceased
- 2005-11-28 KR KR1020097018388A patent/KR101244362B1/ko not_active Expired - Fee Related
- 2005-11-28 SI SI200531130T patent/SI1841432T1/sl unknown
- 2005-11-28 EP EP05817957A patent/EP1841432B1/en not_active Expired - Lifetime
- 2005-11-28 BR BRPI0517128-8A patent/BRPI0517128A/pt not_active IP Right Cessation
- 2005-11-28 RS RSP-2010/0465A patent/RS51506B/sr unknown
- 2005-11-28 MX MX2007006540A patent/MX2007006540A/es active IP Right Grant
- 2005-11-28 KR KR1020077010375A patent/KR20070067189A/ko not_active Ceased
- 2005-11-28 PL PL05817957T patent/PL1841432T3/pl unknown
- 2005-11-28 JP JP2007544016A patent/JP5269415B2/ja not_active Expired - Fee Related
- 2005-11-28 RU RU2007124325/15A patent/RU2397768C2/ru not_active IP Right Cessation
- 2005-11-28 CN CNA2005800395645A patent/CN101060846A/zh active Pending
- 2005-11-28 DE DE602005022939T patent/DE602005022939D1/de not_active Expired - Lifetime
- 2005-11-28 AT AT05817957T patent/ATE476981T1/de active
- 2005-11-28 NZ NZ555075A patent/NZ555075A/en not_active IP Right Cessation
- 2005-11-28 UA UAA200707280A patent/UA91204C2/ru unknown
- 2005-11-28 ES ES05817957T patent/ES2349301T3/es not_active Expired - Lifetime
2007
- 2007-05-29 ZA ZA200704394A patent/ZA200704394B/xx unknown
2010
- 2010-11-10 CY CY20101101012T patent/CY1110886T1/el unknown
2012
- 2012-09-25 US US13/626,236 patent/US9012442B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HRP20100591T1 (hr)	2010-12-31
KR20090101514A (ko)	2009-09-28
DE602005022939D1 (de)	2010-09-23
DK1841432T3 (da)	2010-12-06
CN101060846A (zh)	2007-10-24
US9012442B2 (en)	2015-04-21
PL1841432T3 (pl)	2011-01-31
EP1841432B1 (en)	2010-08-11
JP5269415B2 (ja)	2013-08-21
US20130023512A1 (en)	2013-01-24
CY1110886T1 (el)	2015-06-10
MX2007006540A (es)	2008-01-31
ZA200704394B (en)	2008-09-25
WO2006059344B1 (en)	2006-11-02
EP1841432A1 (en)	2007-10-10
NZ555075A (en)	2011-02-25
AU2005310888B2 (en)	2011-01-06
BRPI0517128A (pt)	2008-09-30
US20100160277A1 (en)	2010-06-24
KR101244362B1 (ko)	2013-03-18
PT1841432E (pt)	2010-10-25
JP2008521884A (ja)	2008-06-26
KR20070067189A (ko)	2007-06-27
ATE476981T1 (de)	2010-08-15
RU2007124325A (ru)	2009-01-10
ES2349301T3 (es)	2010-12-29
RS51506B (sr)	2011-06-30
WO2006059344A1 (en)	2006-06-08
UA91204C2 (ru)	2010-07-12
AU2005310888A1 (en)	2006-06-08
RU2397768C2 (ru)	2010-08-27
US8273732B2 (en)	2012-09-25

Publication	Publication Date	Title
ZA200704394B (en)	2008-09-25	Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection
JP7245289B2 (ja)	2023-03-23	細菌感染症の処置方法
CO5700796A2 (es)	2006-11-30	Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
WO2007112000A3 (en)	2008-01-17	Treatment of pain
WO2009017838A3 (en)	2009-07-02	Combinations of jak-2 inhibitors and other agents
JP2015147783A (ja)	2015-08-20	メチルナルトレキソンを含む医薬処方物
JP2018138578A5 (sl)	2019-08-15
MX2023013890A (es)	2023-12-11	Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
CA2597812A1 (en)	2006-08-17	Parenteral combination therapy for infective conditions with drug resistant bacterium
NO20071711L (no)	2007-07-12	Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel
US20060189584A1 (en)	2006-08-24	Pharmaceutical combinations
Parikh et al.	2011	Preventive analgesia: Effect of small dose of ketamine on morphine requirement after renal surgery
JP7436206B2 (ja)	2024-02-21	細菌感染症を処置する方法
TW200639159A (en)	2006-11-16	Treatment of pain
MX2024011705A (es)	2024-11-08	Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
JP2008540515A (ja)	2008-11-20	嚢胞性線維症を含む重症感染症の処置および管理
PL378713A1 (pl)	2006-05-15	Kompozycje przeciwpierwotniakowe, zawierające diklazuryl
CA2633077A1 (en)	2007-08-02	Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2005092442B1 (en)	2006-11-02	Method and compositions for treatment of chronic neuropathic pain
EP2979694B1 (en)	2018-10-17	Dimercaptosuccinic acid for the treatment of multidrug resistant bacterial infections
CN1709263A (zh)	2005-12-21	抗菌素组合物
WO2022177968A8 (en)	2022-11-17	Therapeutic methods
JP2017508769A5 (sl)	2018-02-22
Vergidis et al.	2017	Beta-Lactamase Inhibitors
Teng et al.	2017	Piperacillin–Tazobactam